Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Breathing motion still remains a major issue that jeopardizes the accuracy of photon- and proton-therapy for thoracic and upper-abdominal tumors, which represent up to 40% of curative radiotherapy treatments. Existing motion management strategies are either simple and costless but lead to futile irradiation of healthy tissues (safety margins), or complex to implement and expensive, limiting their availability in clinical routine (gating, deep-inspiration breath-hold - DIBH, real-time tracking). In addition, the accuracy and efficiency of all these techniques critically depend on tumor motion/position reproducibility over treatment time, which is often degraded by variations of the spontaneous breathing or voluntary apnea. Finally, these techniques are not easily transferrable to proton therapy (PT) in the presence of proton range uncertainties in moving anatomy.
Therefore, we propose an innovative workaround to overcome these complex issues, namely, Mechanically-Assisted and Non-Invasive Ventilation (MANIV). By taking control of the patient's breathing, we previously demonstrated that MANIV can safely regularize and even reduce tumor motion using a volume-controlled ventilation mode (VC), while a slow ventilation mode (SL) can induce repeated DIBH during which the tumor motion is nearly suppressed. Although promising, we have to go a step further into the prospective clinical validation of MANIV applied to existing motion management techniques.
A. Preclinical phase:
B. Clinical phase:
At the end of this project, we will provide recommendations for the clinical implementation of a wide panel of advanced motion mitigation techniques, which would contribute to a major step forward in the management of breathing motion in both photon and proton-therapy.
Radiotherapy of mobile tumors faces many challenges due to breathing-related geometrical uncertainties. Breathing amplitude and frequency may deeply and unexpectedly vary from cycle to cycle, during a treatment fraction (intra-fraction variation) or between fractions (inter-fraction variation) [1]. In Protontherapy (PT), these uncertainties are even worsened by the proton range variations within the traversed moving tissues and the interplay effect between the tumor and spot scanning beam motions. These effects can unpredictively and severely distort dose distribution, and still limit the current indications of PT for thoracic/upper-abdomen cancers [2, 3]. Therefore, several motion mitigation strategies have been developed:
Until now, none of the current strategy provides an entirely satisfactory solution for motion management. The more accurate a technique is, the less efficient it is (treatment time, feasibility, ease of clinical implementation), and vice-versa. By taking control of the patient breathing, MANIV could solve this complex problem. Parkes et al. showed first that MANIV can safely impose a regular breathing pattern on conscious and unsedated patients [12], and could mitigate respiratory motion [13, 14]. Our group has further investigated these ventilation techniques on healthy volunteers [15] and patients [16] to broaden their applicability to radiotherapy of moving tumors. Two ventilation modes appear to be of particular interest for radiotherapy :
In summary, our group has already demonstrated that MANIV was feasible and safe on small cohorts of volunteers and patients, and significantly improved regularity of breathing-related motion or BH monitored by real-time dynamic MRI [15,16]. Based on these very encouraging pre-clinical results, MANIV might thus considerably simplify and improve all motion management strategies in both photon- and proton therapies. However, further clinical investigations are still required in real treatment conditions to validate its use for clinical routine. These include the clinical implementation of the ventilator in a LINAC environment, and the quantification of the added value of MANIV for the above-mentioned mitigation techniques.
Research project We plan first to implement MANIV in the patient workflow and to validate and optimize our onboard imaging procedure to quantify residual motion or motion regularity. Then, we will conduct 4 clinical studies, each investigating the added value of MANIV for a specific motion management strategy.
A) Preclinical phase :
MANIV has been interfaced with the control room of our LINACs to monitor the MANIV breathing parameters. Intra-fraction motion will be monitored during gating treatments using Cone-Beam CT (CBCT). Computing motion from these devices will require the use of experimental mathematical models to infer the three-dimensional trajectory of a tumor from its two-dimensional X-rays projections. Five models have been reported in the literature [18,19,20,21,22]. The one of Poulsen et al [22] based on a probabilistic approach is the most accurate with a submillimetric residual error [23]. We have already validated this method in the environnement our treatment machines with a dynamic thorax phantom (model 008A CIRS®), and we are now able to analyze intra-fraction motion from imaging data of patients treated on our LINACs.
B) Clinical phase:
For all clinical studies, subjective and objective patient's tolerance will be monitored during MANIV with comfort questionnaires (Likert scales and visual analogue scale) and vital parameters (Heartbeat Rate, SpO2, etCO2). Statistical power analysis were performed using the PASS 14.0.7 statistical software.
Improving respiratory gating with MANIV-induced DIBH for liver and lung cancers RT:
Improving respiratory gating with MANIV-Induced DIBH for breast RT:
Improving respiratory real-time tracking by VC mode:
Mechanically-induced breath-holds for gated PBS-PT:
Design: Non-comparative observational prospective study.
Population: Patients included in study n°1
Method: data on tumor position and its residual motion from patients included in the study n°1 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCL-IREC ) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare [25], coupled with log-file acquisitions [26]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach.
Primary outcome: dose delivered at 95, 98 and 100% of the volume of each tumor.
Statistical power analysis : not applicable. Patients from study n°1 (Improving respiratory gating by SL mode) will be included.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm N°1 - Standard treatment-Breast DIBH | Active Comparator | Patients will be treated during spontaneous breath hold wich is considered as the gold-standard radiotherapy treatment for left breast cancer. |
|
| Arm N°2 - Interventional -Breast MANIV DIBH | Experimental | Irradiation will take place during DIBH induced by MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 30 seconds to allow the complete delivery of a treatment beam. |
|
| Arm N°3 - Interventional -Liver/Lung MANIV DIBH | Experimental | Irradiation will take place during DIBH induced by the MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 30 seconds to allow the complete delivery of a treatment beam [13]. Prior to treatment, a radio-opaque fiducial will be implanted in the tumor by an interventional radiologist, to facilitate the tumor position monitoring from onboard imaging. Residual tumor baseline shift and motion will thus be measured during beam delivery, and used to recompute the optimal safety margins that ensure an adequate dose coverage of at least 90% of tumors, according to literature recommendations [24]. We will also compare these safety margins computed under MANIV condition with those routinely applied in free-breathing condition to estimate the gain in terms of margin reduction. |
|
| Arm N°4 - Interventional -Liver/Lung MANIV VC | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MANIV | Device | mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac |
|
| Measure | Description | Time Frame |
|---|---|---|
| Validation of MANIV-optimized Gating strategy for breast tumors | mean breast gland 3D displacements during treatment delivery. | through study completion, an average of 3 weeks |
| Validation of MANIV-optimized Gating strategy for lung and liver tumors | Proportion of patients successfully treated with MANIV | through study completion, an average of 2 weeks |
| Validation of MANIV-optimized Tracking strategy | Average time required to deliver a fraction | through study completion, an average of 2 weeks |
| In silico evaluation of viability with treatment by protontherapy in SL mode | % of CTV volume receiving at least a given dose level by patient | through study completion, an average of 2 weeks |
Not provided
Not provided
Inclusion Criteria:
Validation of the MANIV-optimized gating strategy for breasrt tumors :
Patients with left breast tumors eligible for radiation therapy with breath hold technique.
Validation of the MANIV optimized Gating strategy for lung/liver tumors:
Patients with lung (primary or secondary) or liver (primary or secondary) tumors eligible for stereotactic radiation therapy.
Validation of the MANIV-optimized Tracking strategy for liver tumors:
Part 1: Patients with hepatic neoplasia (primary or secondary) eligible for stereotactic radiation therapy on the Cyberknife® of the Oscar Lambret center in Lille (France)..
Part 2: Patients with hepatic neoplasia (primary or secondary) treated by respiratory tracking on the Cyberknife® of the Oscar Lambret center in Lille (France).
4 - Evaluation of a proton therapy treatment delivered in silico to mobile tumors with MANIV in DIBH mode : Patients included in the study on the optimization of the Gating strategy.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Geneviève Van Ooteghem, MD,PhD | Cliniques Universitaires Saint-Luc, Brussels, Belgium | Study Chair |
| David Pasquier, MD,PhD | Centre Oscar Lambret, Lille, France | Study Chair |
| Xavier Geets, MD,PhD | Cliniques Universitaires Saint-Luc, Brussels, Belgium | Principal Investigator |
| Loïc Vander Veken, MD | Cliniques Universitaires Saint-Luc,Brussels, Belgium | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cliniques Universitaires Saint-Luc | Woluwe-Saint-Lambert | Brussels Capital | 1200 | Belgium |
Not provided
Multicentric prospective interventional or retrospective observational study depending on the sub-part considered. It is segmented into 5 sub-parts each investigating the interest of MANIV for a specific motion management technique.
Not provided
Not provided
Not provided
Not provided
Patients will be ventilated by VC mode during their treatment. For each fraction, the treatment time, the number of reconstructions of the tracking model and the correlation errors of the model will be collected. The same information will be extracted from a matched retrospective cohort treated by tracking in spontaneous breathing.
|
| Arm N°5 -Liver/Lung MANIV DIBH for PT | Other | Data on tumor position and its residual motion from patients included in the arm n°3 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCLouvain - IREC) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare [25], coupled with log-file acquisitions [26]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach. |
|
| Spontaneous DIBH | Other | performed on Varian® Halcyon LINAC and Infinity Elekta® linac |
|